Moderna

Moderna's predictability score of 27/100 is expected for a biotechnology firm, particularly one that experienced an unprecedented surge and subsequent decline in demand for its primary product. The extreme volatility introduced by the pandemic's unique market conditions has made forecasting future performance incredibly challenging.

The 3-year revenue CAGR of -53.4% underscores this inherent unpredictability, demonstrating a rapid shift from hyper-growth to significant contraction. Furthermore, the massive negative TTM Operating Margin of -203.5% and TTM Net Income of $-7.20B highlight a complete lack of earnings stability and operational consistency.

Biotechnology companies inherently face high unpredictability due to the lengthy and uncertain nature of drug development, clinical trials, regulatory approvals, and market adoption.

For Moderna, this unpredictability is amplified by the need to pivot from a single, high-demand product to a diversified pipeline, with no clear indication of when or if its future products will achieve commercial success and stabilize its financial profile.